Account
Insider Insights
09.03.2023
CMS declines to revise coverage for FDA-approved t...

CMS denies coverage of FDA-approved treatments that target amyloid for Alzheimer's disease unless th...

Read more
Insider Insights
06.03.2023
The Project Orbis initiative

The Project Orbis initiative is an international partnership between medicines regulators in the UK,...

Read more
Insider Insights
06.03.2023
Italy AIFA reports on manufacturer paybacks

Collectively, companies still owe AIFA €370 million of the €2.8 billion that industry has to rep...

Read more
Newsletter
17.02.2023
PMA Insights: Week 7

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Articles
17.02.2023
How will governments face the cost of medical mira...

Among the most expensive therapies are gene therapies that show promise to transform inherited disor...

Read more
Insider Insights
09.02.2023
New criteria for ATMPs which must follow quality r...

The Federal Joint Committee (G-BA) has set out criteria for ATMPs which are likely to require qualit...

Read more
Articles
08.02.2023
Which countries fund early access and why don’t ...

The provision of funding for Early Access Programmes is not ubiquitous. We explore which EU5 countri...

Read more
Articles
11.01.2023
What are the 5 Pricing & Market Access trends ...

Our experts provide an overview of the five key trends that could shape the pricing and market acces...

Read more
30.11.2022
Reflecting on the Pricing & Market Access tren...

Our experts reflect on the trends that shaped the European pricing and market access landscape in 20...

Read more
Newsletter
02.11.2022
PMA Insights: Week 44

We summarise four handpicked articles from pharmaceutical, pricing and market access that are worth ...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.